Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Next-gen ADCs upgrade structures, expand targets and face multiple clinical challenges.
2026 oncology M&A surges driven by patent cliffs, novel modalities and booming Chinese biotech licensing.
Stage, mechanism and biomarkers shape oncology asset risks and deal values.
Four core clinical factors jointly determine rNPV and transaction pricing of oncology assets.
BsAb transactions surge amid mature platforms, validated dual targets and cross-field expansion.
ADC deals surge driven by payload innovation, patent risks and rising clinical value.
Validated RPT booms with massive pharma M&A yet faces multiple clinical and supply hurdles.
BEP/EP regimens cure TGCTs; prioritize dose intensity, fertility, and long-term toxicity care.
GLP-1 and dual agonists benefit cardiometabolic diseases with proven CV and renal protection.
Deep learning boosts MRI-based NPC detection, segmentation and radiotherapy planning.
EBV status shapes NPC genomics, immunity and personalized treatment strategies.
Multiple salvage options exist for recurrent NPC with distinct pros and cons.
Two PD-1 combinations improve survival for recurrent metastatic NPC with distinct toxicities.
Circulating EBV DNA enables effective early screening and mortality reduction for NPC.
AI boosts MRCP accuracy for distinguishing benign and malignant biliary strictures.
Liver flukes trigger CCA via inflammation, DNA damage and epigenetic changes.
Lenvatinib shows distinct efficacy, safety and dosing differences between trials and real-world use.
Three targeted drugs for CCA differ in efficacy, safety, resistance and medication sequence.
CCA subtypes differ greatly in molecular alterations, assays and targeted therapies.
Two chemoimmunotherapies become new standards for advanced BTC with distinct trial profiles.